New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

New York Plastic Surgical Group (NYPS Group) and Deep Blue Med Spa (DBMS) are proud to announce that they have once again been recognized by Allergan Aesthetics as the #1 provider in New York State, marking the second consecutive year earning this distinction. In addition, the practices have been ranked Top 50 in the nation for 2026, placing them among an elite group of aesthetic providers across the United States.

This recognition reflects NYPS Group and Deep Blue Med Spa's continued leadership in aesthetic medicine and their longstanding commitment to delivering advanced, evidence-based treatments performed by highly trained medical professionals.

Allergan Aesthetics, an AbbVie company, develops and manufactures some of the most recognized brands in medical aesthetics, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers, Skinvive™, CoolSculpting®, CoolTone®, DiamondGlow®, and SkinMedica®, among others. Rankings are determined through the Allergan Partner Privileges program, which acknowledges practices based on their experience and volume of Allergan aesthetic products and treatments.

Earning the #1 ranking in New York for the second year in a row underscores the trust patients place in NYPS Group and Deep Blue Med Spa for injectable treatments, body contouring, and comprehensive aesthetic services. National Top 50 placement further distinguishes the practices as leaders in the field.

"This continued recognition from Allergan Aesthetics reflects the dedication of our surgeons, physician assistants, nurse practitioners, and aesthetic providers who prioritize patient safety, education, and natural-looking results," said NYPS Group President, Tommaso Addona, MD, FACS. "It is an honor and a privilege to serve our patients with advanced treatments backed by science and delivered with precision."

For patients, this designation signals a high level of experience with Allergan's portfolio of products and access to exclusive offerings and rewards through Allergan's programs. It also reflects ongoing investment in provider training, as multiple NYPS Group and Deep Blue Med Spa clinicians have been selected to serve as national Allergan Medical Institute (AMI) trainers, contributing to peer education across the country.

About New York Plastic Surgical Group and Deep Blue Med Spa
As the largest and longest-running private and academic plastic surgery practice in the United States, New York Plastic Surgical Group includes more than 20 experienced plastic surgeons and maintains over 10 offices throughout the metropolitan area. In addition to its surgical practice, NYPS Group operates Deep Blue Med Spa, which provides non-surgical aesthetic treatments in multiple New York locations. Together, the practices are known for clinical excellence, comprehensive patient care, and a commitment to advancing the field of aesthetic medicine through education and innovation.

About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), develops, manufactures, and markets a portfolio of leading aesthetics brands and products worldwide. Its offerings include facial injectables, body contouring technologies, skin care, and more. Through ongoing research and innovation, Allergan Aesthetics remains committed to advancing science-based solutions in aesthetic medicine.

Attachment


Jeanine DiGennaro Director of Marketing & Communications (516) 629-3835 jdigennaro@nyplasticsurgical.com New York Plastic Surgical Group (516) 742-3404 

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to... Keep Reading...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6... Keep Reading...
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin... Keep Reading...
SVN-114 selected as the lead candidate for PTSD discovery programme

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...
Scientists examining a sample under a microscope in a lab setting.

Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.The agreement,... Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...

Interactive Chart

Latest Press Releases

Related News